-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We lower our target to $90 from $97, on a forward P/E of 13.7x our 2027 EPS, below ITGR's 10-year historical forward average of 17.6x. We cut our 2026 EPS view to $6.16 from $6.74 as we expect some margin pressures ahead, and decrease 2027 to $6.57 from $6.88. Adj. operating margin was -230 bps Y/Y to 13.9% in Q1, primarily due to lower fixed cost absorption from reduced sales volumes. ITGR's Q1 results came in line with previous guidance, with adj. EPS of $1.20 and revenue of $440M. Yet, ITGR significantly lowered its full-year 2026 outlook, citing recent forecast reductions from customers, primarily in the electrophysiology market, and additional risk adjustments made across the portfolio. The new guidance projects a Y/Y reported sales decline of 1%-3% and lowered adj. EPS of $5.83-$6.40. Given these challenges, we think the announced strategic review could be timely as ITGR aims to explore opportunities to maximize shareholder value, including a potential transaction or continuing its stand-alone strategy.